Nyse Rdy Financials Company Overview and Results

Let's take a closer look at NYSE RDY financials. The company is a leading provider of residential and commercial real estate services.

RDY has a diverse revenue stream, with a significant portion coming from its mortgage banking business.

The company's financial performance is impressive, with a net income of $83.3 million in 2020.

Dr. Reddy's Laboratories has reported a steady increase in revenue, with estimates suggesting $3,931 million in 2026, $4,017 million in 2027, and $4,325 million in 2028.

The company's dividend has remained consistent at $0.10 per share from 2026 to 2028, resulting in a dividend yield of 0.66%, 0.65%, and 0.69% respectively.

In terms of earnings per share (EPS), Dr. Reddy's has reported $0.72 in 2026, $0.63 in 2027, and $0.71 in 2028.

Here's a breakdown of the company's revenue estimates for the next few years:

Dr. Reddy's has also reported a net profit of $607 million in 2026, $543 million in 2027, and $608 million in 2028, with a net profit adjusted for special items of $602 million in 2026, $547 million in 2027, and $608 million in 2028.

The company's cash flow from operations has been relatively stable, with $749 million in 2026, $732 million in 2027, and $738 million in 2028.

Dr. Reddy's Laboratories has been able to generate a significant amount of cash from its operations, with free cash flow of $446 million in 2026, $482 million in 2027, and $483 million in 2028.

The company's research and development expenses have increased over the years, from $313 million in 2026 to $335 million in 2028.

Dr. Reddy's has also reported a significant increase in its shareholder's equity, from $4,355 million in 2026 to $5,261 million in 2028.

The company's total assets have also increased, from $5,726 million in 2026 to $6,677 million in 2028.

According to the earnings estimates, the average estimate for Dr. Reddy's Laboratories is $0.155 USD in the current quarter, $0.145 USD in the next quarter, and $0.723 USD for the current year.

On a similar theme: Ally Financial Announces Second Quarter 2024 Financial Results

Dr. Reddy's Laboratories is a global pharmaceutical company that operates in North America, Europe, India, Russia, and internationally.

The company was founded by Kallam Anji Reddy on February 24, 1984, and is headquartered in Hyderabad, India.

Dr. Reddy's Laboratories is an integrated pharmaceutical company that manufactures and markets pharmaceutical products through its various segments.

The Global Generics segment focuses on manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient.

The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API.

The Others segment includes the operations of the company's subsidiary.

Earnings for Dr. Reddy's Laboratories are forecast to decline by an average of 1.2% per year for the next 3 years.

The current share price of ₹14.87 is relatively stable, considering the 52 Week High of ₹16.17 and the 52 Week Low of ₹12.26.

Over the past 3 years, the share price has increased by 37.74%, while the 1 Year Change is -4.78%. The 5 Year Change is 14.58%, and the Change since IPO is a remarkable 1,372.28%.

Here are the key share price changes for Dr. Reddy's Laboratories over the past year:

RDY's price volatility is relatively low, with an average weekly movement of 2.8%, compared to the Pharmaceuticals Industry Average Movement of 9.5% and the Market Average Movement of 6.5%.

Earnings are forecast to decline by an average of 1.2% per year for the next 3 years. This decline may seem small, but it can add up over time.

A decline of 1.2% per year may not seem like much, but it can lead to a significant decrease in earnings over the course of 3 years.

Dr. Reddy's Laboratories has seen its share price fluctuate over the years, with a 52-week high of ₹16.17 and a low of ₹12.26. The current share price is ₹14.87.

The company's beta, which measures its volatility compared to the market, is 0.33. This suggests that Dr. Reddy's shares are less volatile than the overall market.

In the past year, the company's share price has experienced a 1.09% change, while the 1-year change is -4.78%. This indicates a decline in value over the past 12 months.

Here's a summary of the company's share price performance over the past 5 years:

The company's share price has increased significantly since its IPO, with a change of 1,372.28%.

The financial statements of NYSE RDY provide a clear picture of the company's financial health. The total liabilities have increased from $1,230.31 in 2019 to $1,823.08 in 2025.

A closer look at the balance sheet reveals that the equity has grown significantly, reaching $3,944.73 in 2025. This represents a 15.96% increase from the previous year.

The company's long-term liabilities per share have also seen an uptick, standing at $0.36 in 2025. This is a notable increase from the $0.07 recorded in 2023.

Here's a breakdown of the balance sheet total change in percentage:

The balance sheet total has shown a steady increase, reaching $5,767.81 in 2025.

Dr. Reddy's Laboratories Ltd. has a history of paying dividends to its shareholders. The company's dividend has been steadily increasing over the years, with a high of $0.23 in 2013.

In terms of the dividend yield, it has ranged from 0.46% in 2021 to 1.39% in 2009. The dividend is paid in USD, and the company has maintained this currency for its dividend payments.

Here is a breakdown of the company's dividend payments over the past few years:

The company has also announced its earnings release dates for the upcoming years, with the Q2 2026 earnings release scheduled for October 24, 2025.

Dr. Reddy's Laboratories has a dividend calendar that shows the company's dividend payments over the years.

The company has been paying dividends since 2009, with the first payment being $0.13 USD.

In 2013, the company paid a dividend of $0.23 USD, which was the highest amount paid in a single year.

Here is a list of Dr. Reddy's Laboratories' dividend payments from 2010 to 2019:

The company's dividend yield has also varied over the years, with the highest yield being 1.39% in 2009.

Dr. Reddy's Laboratories has also announced its future dividend payments, with the next payment expected to be $0.07 USD in 2025.

A fresh viewpoint: Nyse T Dividend

Dr. Reddy's Laboratories has a history of holding Annual General Meetings, with the highest actual EPS being 0.808 USD in 2024.

The company's Earnings Reports have also been a regular occurrence, with the lowest actual EPS being 0.014 USD in Q4 2022.

In 2025, Dr. Reddy's Laboratories reported an actual EPS of 0.221 USD for Q4 Earnings Release.

Here's a breakdown of the company's Earnings Reports from 2023 to 2025:

The dates of these Earnings Reports are: Q2 2024 (10/27/2023), Q3 2024 (01/30/2024), Q4 2024 (05/07/2024), Q1 2025 (07/27/2024), Q2 2025 (11/05/2024), Q3 2025 (01/23/2025), and Q4 2025 (05/09/2025).

Note the varying actual EPS values for each quarter, indicating fluctuations in the company's financial performance.

When it comes to shareholder returns, it's essential to consider the performance of Dr. Reddy's Laboratories (RDY) against its peers and the broader market.

RDY's 7-day return stands at 5.7%, significantly outpacing the US Pharmaceuticals industry's 0.2% return and the US Market's -0.1% return.

The company's 1-year return of -4.8% is slightly better than the US Pharmaceuticals industry's -5.4% return, but lags behind the US Market's 16.6% return.

Here's a comparison of RDY's returns with the US Pharmaceuticals industry and the US Market:

It's worth noting that RDY exceeded the US Pharmaceuticals industry's return over the past year, but underperformed the US Market.